|
| |
Nabriva Therapeutics raises Euro 15 Million (USD 22 Million)
Vienna, Austria- October 28, 2009 - Nabriva Therapeutics, a biotechnology
company focused on developing a new class of antibiotics for serious infections
caused by resistant pathogens, today announced the closing of a EUR 15 Million
financing, bringing the total equity funding raised by the company to EUR 57.4
Million (USD 84 Million) since it’s foundation in 2006.
Nabriva’s existing investors Nomura Phase 4 Ventures, HBM Partners, Wellcome
Trust, GLS Ventures, and Novartis Venture Fund participated in this round.
Dr. David Chiswell, CEO of Nabriva Therapeutics said: "These additional funds
extend Nabriva’s cash reach into 2011 and will fund the development of our
systemic pleuromutilin program up to and including the generation of phase II
efficacy data in the second half of 2010 .”
Ralf Schmid, CFO of Nabriva added: “We are delighted that our existing investors
have shown such a solid commitment to Nabriva and its drug candidates.”
- ends -
About Nabriva Therapeutics
Nabriva Therapeutics is a biotechnology company focused on developing a new
class of antibiotics for the treatment of serious infections caused by resistant
pathogens. The Company’s systemically available pleuromutilin program is
generating extensive clinical phase I data ahead of the Phase II program
starting in 2010 with efficacy data in cSSSI expected in the second half of
2010. In addition, Nabriva Therapeutics’ topical pleuromutilin product
candidate, BC-7013, is also in clinical phase I.
Nabriva Therapeutics has a proven track record in world-class medicinal
chemistry, clinical expertise, a seasoned management team and solid IP. Nabriva
Therapeutics is located in Vienna, Austria.
For more information on Nabriva Therapeutics please visit
www.nabriva.com .
Contact:
Nabriva Therapeutics AG
Dr David Chiswell
CEO
T +43 (0)1 740 93-0
OFFICE@NABRIVA.COM
College Hill Life Sciences
Dr Douglas Pretsell
Senior Account Director
T +49 (0)89 57001806
douglas.pretsell@collegehill.com
| |
|
